Mediwound Ltd. income statement

In fiscal 2025, Mediwound Ltd. reported revenue of $17.0m, down 16.1% on the year before, operating income of −$25.3m (a -149.0% margin) and net income of −$23.9m, or −$2.10 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mediwound Ltd.: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	1	2	2	3	32	22	24	26	19	20	17
Cost of revenue	3	2	2	2	12	14	15	13	15	18	14
Gross profit	−2	−1	1	1	20	8	9	13	4	3	3
Research and development	6	7	5	4	5	8	10	10	7	9	14
Selling and marketing	0	0	0	0	0	0	0	0	0	0	1
Operating income	−21	−20	−14	−4	4	−9	−11	−8	−15	−19	−25
Interest expense	—	—	—	—	0	0	0	0	0	1	1
Income before tax	—	—	—	—	2	−9	−14	−20	−7	−30	−24
Income tax	—	—	—	—	0	0	0	0	0	0	0
Net income	−22	−19	−22	−1	5	−9	−14	−20	−7	−30	−24
Diluted EPS	—	—	—	—	—	−$16.66	−$3.48	−$3.93	−$0.75	−$3.03	−$2.10
Diluted shares (average)	3m	3m	3m	4m	4m	4m	4m	5m	9m	10m	11m
EBITDA	−21	−20	−13	−3	5	−8	−11	−8	−15	−19	−25

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MDWD vs PRQR CTMX vs MDWD CELU vs MDWD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mediwound Ltd.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mediwound Ltd.